I would like to introduce Accrelist Ltd as I see great potential in its aesthetic business.
With the increasing social acceptance in the aesthetic medical services sector, it would bring in long-term growth for this Company and this is evidenced from the financial results where from the date of completion of the acquisition till the financial year ended 31 March 2019,
Besides growth on the increase in medical aesthetic clinics, the Company is expanding its business on clinical skin care products. Accrelist would carry non-ODM skin products which are renowned brands from Korea. With this, a retail shop would be set up for such and this is expected to be sold online.
I would consider its current share price is too low as compared to its NAV per share. Current share price is only $0.036 vs NAV per share of $0.15!
